Launch represents Vectura Fertin Pharma's first medical cannabis CBD lozenge to be introduced in Canada Launch follows announcement of commercial collaboration between Cogent International, a Vectura Fertin Pharma subsidiary, and Aurora to leverage Aurora's Canadian medical cannabis patient platform Collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in Canada EDMONTON, AB , and STAMFORD, Conn. , Sept. 9, 2024 /PRNewswire/ - Aurora Cannabis Inc.
("Aurora") (NASDAQ: ACB ) (TSX: ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce the launch of the newly developed Luo CBD lozenge. The high-quality CBD lozenge was developed by Vectura Fertin Pharma and adheres to stringent safety, quality and regulatory standards to address unmet medical and health needs.
It is the first of Vectura Fertin Pharma's medical cannabis products to launch in Canada . The CBD lozenge is being manufactured, packaged and labelled by Cogent, a Vectura Fertin Pharma subsidiary, for sale and will be distributed by Aurora through its leading direct-to-patient e-commerce platform. The CBD lozenge, which has a novel dissolvable format and is easy to dose, is now available for patients on Aurora's Canadian medical cannabis patient platform as authorised by healthcare professionals.
Miguel Martin , CEO for Aurora said: "As the leading provider of me.